Tegoprazan

• Description :

  Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H+/K+-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H+/K+-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases[1][2][3].

• CAS Number :

  [942195-55-3]

• Product Name Alternative :

  CJ-12420; RQ-00000004

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Na+/K+ ATPase; Potassium Channel; Proton Pump

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Tegoprazan.html

• Concentration :

  10mM

• Purity :

  99.76

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  FC1=CC(F)=C2[C@@H](OC3=CC(C(N(C)C)=O)=CC4=C3N=C(C)N4)CCOC2=C1

• Molecular Formula :

  C20H19F2N3O3

• Molecular Weight :

  387.38

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [2]Son M, et al. Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function[J]. Front Immunol. 2022 May 25;13:870817. |[3]Kim DK, et al. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease[J]. J Pharmacol Exp Ther. 2019 Jun;369 (3) :318-327. |[1]Takahashi N, et al. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility. J Pharmacol Exp Ther. 2018 Feb;364 (2) :275-286.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched